Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2018
Price : $35 *
At a glance
- Drugs Irinotecan (Primary) ; Cyclophosphamide
- Indications Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Merrimack Pharmaceuticals
- 17 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
- 17 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2020.
- 05 Apr 2017 Preliminary pharmacokinetic and safety results (n=16) presented at the 108th Annual Meeting of the American Association for Cancer Research.